To investigate the association of the genetic polymorphisms of the plasminogen activator inhibitor type 1 (PAI-1) gene with the risk of ischemic stroke (IS) in subjects with type 2 diabetes mellitus (T2DM).
Materials and Methods:
Using a case-control study design, 175 individuals with T2D and IS were enrolled in the case group and 125 patients with T2D without IS were enrolled as controls. The clinical characteristics of the groups were compared, and genotypes were determined by direct DNA sequencing.
Results:
Male and hypertensive subjects were higher in the IS group (p = 0.002 and 0.014, respectively). High-density lipoprotein (HDL) and apolipoprotein A1 (APOA1) were lower in the IS group (p = 0.011 and 0.025, respectively); hemoglobin A1c (HbA1c), total homocysteine (tHcy), and FT4 levels were higher in the IS group (p = 0.022, 0.003, and 0.008, respectively). The 4G/4G, 4G/5G, and 5G/5G genotype frequencies were 40.0%, 46.4%, and 13.6% in the control group versus 31.4%, 52.0% and 16.6% in the IS group, respectively. Hypertension (odds ratio [OR] = 1.953, p = 0.020), tHcy (OR = 1.059, p = 0.029), thyroid-stimulating hormone (OR = 0.876, p = 0.039), and the PAI-1 genotype dominant allele model (OR = 1.748, p = 0.047) were associated with IS by multivariate analysis.
Conclusion:
The PAI-1 genotype dominant allele model was a risk factor for IS in patients with T2DM of Jinan, China.
Get full access to this article
View all access options for this article.
References
1.
Al-RubeaanK, Al-HussainF, YoussefAM, et al. (2016) Ischemic stroke and its risk factors in a registry-based large cross-sectional diabetic cohort in a country facing a diabetes epidemic. J Diabetes Res, 2016:4132589.
2.
ArboixA, Lopez-GrauM, CasasnovasC, et al. (2006a) Clinical study of 39 patients with atypical lacunar syndrome. J Neurol Neurosurg Psychiatry, 77:381-384.
3.
ArboixA, MilianM, OliveresM, et al. (2006b) Impact of female gender on prognosis in type 2 diabetic patients with ischemic stroke. Eur Neurol, 56:6-12.
4.
BangCO, ParkHK, AhnMY, et al. (2001) 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and insertion/deletion polymorphism of the tissue-type plasminogen activator gene in atherothrombotic stroke. Cerebrovasc Dis, 11:294-299.
5.
BevanS, TraylorM, Adib-SamiiP, et al. (2012) Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke, 43:3161-3167.
6.
BrownDL, MowlaA, McDermottM, et al. (2015) Ischemic stroke subtype and presence of sleep-disordered breathing: the BASIC sleep apnea study. J Stroke Cerebrovasc Dis, 24:388-393.
7.
BuckovaD, Izakovicova HollaL, VachaJ (2002) Polymorphism 4G/5G in the plasminogen activator inhibitor-1 (PAI-1) gene is associated with IgE-mediated allergic diseases and asthma in the Czech population. Allergy, 57:446-448.
8.
BurzottaF, Di CastelnuovoA, AmoreC, et al. (1997) 4G/5G polymorphism in the promoter region of the PAI-1 gene is not a risk factor for familial myocardial infarction in subjects over 45 years. Thromb Haemost, 78:1294-1295.
9.
BurzottaF, IacovielloL, Di CastelnuovoA, et al. (2003) 4G/5G PAI-1 promoter polymorphism and acute-phase levels of PAI-1 following coronary bypass surgery: a prospective study. J Thromb Thrombolysis, 16:149-154.
10.
CasasJP, HingoraniiAD, BautistaLE, et al. (2004) Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls. Arch Neurol, 61:1652-1661.
11.
ChaiY, GuB, QiuJR, et al. (2012) The uncoupling protein -866G > a polymorphism is associated with the risk of ischemic stroke in Chinese type 2 diabetic patients. CNS Neurosci Ther, 18:636-640.
12.
ChenCH, EngHL, ChangCJ, et al. (2003) 4G/5G promoter polymorphism of plasminogen activator inhibitor-1, lipid profiles, and ischemic stroke. J Lab Clin Med, 142:100-105.
13.
ChenGY, LiL, DaiF, et al. (2015) Prevalence of and Risk Factors for Type 2 Diabetes Mellitus in Hyperlipidemia in China. Med Sci Monit, 21:2476-2484.
14.
DawsonS, HamstenA, WimanB, et al. (1991) Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb, 11:183-190.
15.
de Paula SabinoA, RibeiroDD, DominguetiCP, et al. (2011) Plasminogen activator inhibitor-1 4G/5G promoter polymorphism and PAI-1 plasma levels in young patients with ischemic stroke. Mol Biol Rep, 38:5355-5360.
16.
El-KoussyM, SchrothG, BrekenfeldC, et al. (2014) Imaging of acute ischemic stroke. Eur Neurol, 72:309-316.
EndlerG, LalouschekW, ExnerM, et al. (2000) The 4G/4G genotype at nucleotide position -675 in the promotor region of the plasminogen activator inhibitor 1 (PAI-1) gene is less frequent in young patients with minor stroke than in controls. Br J Haematol, 110:469-471.
19.
ErgulA, Kelly-CobbsA, AbdallaM, et al. (2012) Cerebrovascular complications of diabetes: focus on stroke. Endocr Metab Immune Disord Drug Targets, 12:148-158.
20.
ErikssonP, Kallin B van ‘t HooftFM, et al. (1995) Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci U S A, 92:1851-1855.
21.
GreenJB (2014) Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. Postgrad Med, 126:190-204.
22.
HanL, WuQ, WangC, et al. (2015) Homocysteine, Ischemic Stroke, and Coronary Heart Disease in Hypertensive Patients: A Population-Based, Prospective Cohort Study. Stroke, 46:1777-1786.
23.
HassanA, MarkusHS (2000) Genetics and ischaemic stroke. Brain, 123:1784-1812.
24.
HuX, ZanX, XieZ, et al. (2017) Association between plasminogen activator inhibitor-1 genetic polymorphisms and stroke susceptibility. Mol Neurobiol, 54:328-341.
25.
IacovielloL, BurzottaF, Di CastelnuovoA, et al. (1998) The 4G/5G polymorphism of PAI-1 promoter gene and the risk of myocardial infarction: a meta-analysis. Thromb Haemost, 80:1029-1030.
26.
JoodK, LadenvallP, Tjarnlund-WolfA, et al. (2005) Fibrinolytic gene polymorphism and ischemic stroke. Stroke, 36:2077-2081.
27.
KatakamiN, TakaharaM, KanetoH, et al. (2010) Accumulation of gene polymorphisms related to plaque disruption and thrombosis is associated with cerebral infarction in subjects with type 2 diabetes. Diabetes Care, 33:390-395.
28.
KawamuraT (2003) [Cerebrovascular disease and diabetic patients with hypertension]. Nihon Rinsho, 61:1175-1180.
29.
KurukulasuriyaLR, GovindarajanG, SowersJ (2006) Stroke prevention in diabetes and obesity. Expert Rev Cardiovasc Ther, 4:487-502.
30.
LeonardsCO, SchneiderHJ, LimanTG, et al. (2014) Thyroid-stimulating hormone, white matter hyperintensities, and functional outcome in acute ischemic stroke patients. Cerebrovasc Dis Extra, 4:61-68.
31.
MeschiaJF, BushnellC, Boden-AlbalaB, et al. (2014) Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45:3754-3832.
32.
MoehleckeM, KramerCK, LeitaoCB, et al. (2010) ENPP1 K121Q polymorphism and ischemic heart disease in diabetic patients]. Arq Bras Cardiol, 94:157-161, 168-173, 159-163.
33.
MoskauS, SmolkaK, SemmlerA, et al. (2010) Common genetic coagulation variants are not associated with ischemic stroke in a case-control study. Neurol Res, 32:519-522.
34.
PhippsMS, JastreboffAM, FurieK, et al. (2012) The diagnosis and management of cerebrovascular disease in diabetes. Curr Diab Rep, 12:314-323.
35.
QiQ, WorkalemahuT, ZhangC, et al. (2012) Genetic variants, plasma lipoprotein(a) levels, and risk of cardiovascular morbidity and mortality among two prospective cohorts of type 2 diabetes. Eur Heart J, 33:325-334.
36.
RidkerPM, HennekensCH, LindpaintnerK, et al. (1997) Arterial and venous thrombosis is not associated with the 4G/5G polymorphism in the promoter of the plasminogen activator inhibitor gene in a large cohort of US men. Circulation, 95:59-62.
37.
RoestM, BangaJD (2003) Editorial comment—genetic make-up for increased PAI-1 expression protects against stroke. Stroke, 34:2828-2829.
38.
RoestM, van der SchouwYT, BangaJD, et al. (2000) Plasminogen activator inhibitor 4G polymorphism is associated with decreased risk of cerebrovascular mortality in older women. Circulation, 101:67-70.
39.
TziomalosK, SpanouM, BouzianaSD, et al. (2014) Type 2 diabetes is associated with a worse functional outcome of ischemic stroke. World J Diabetes, 5:939-944.
40.
UnalE, MunganS, BilenS, et al. (2013) The effects of lipoprotein(a) and homocysteine on prognosis and risk factors in acute ischemic stroke. Int J Neurosci, 123:532-536.
41.
WangX, ChengS, BrophyVH, et al. (2009) A meta-analysis of candidate gene polymorphisms and ischemic stroke in 6 study populations: association of lymphotoxin-alpha in nonhypertensive patients. Stroke, 40:683-695.
42.
WeberR, GoertlerM, BenemannJ, et al. (2009) Prognosis after cryptogenic cerebral ischemia in patients with coagulopathies. Cerebrovasc Dis, 28:611-617.
43.
WhitworthJA (2003) 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens, 21:1983-1992.
44.
WiklundPG, NilssonL, ArdnorSN, et al. (2005) Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: replicated findings in two nested case-control studies based on independent cohorts. Stroke, 36:1661-1665.
45.
WongTY, PoonP, SzetoCC, et al. (2000) Association of plasminogen activator inhibitor-1 4G/4G genotype and type 2 diabetic nephropathy in Chinese patients. Kidney Int, 57:632-638.
46.
WuYT, LiuYN, WuSL, et al. (2012) [Study on the effects of different risk stratifications in patients with diabetes mellitus: a clinical endpoint event]. Zhonghua Liu Xing Bing Xue Za Zhi, 33:88-91.
ZhuS, HuJ, McCoyTP, et al. (2015) Socioeconomic status and the prevalence of type 2 diabetes among adults in Northwest China. Diabetes Educ, 41:599-608.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
